Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Access to healthy food would address the rising rates of obesity, diabetes and heart disease and the psychological issues ...

Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose ...

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

Want to live longer? A new groundbreaking study reveals what to focus on for a healthy, long life and it is not weight loss.

Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...

The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Novo Nordisk's Karsten Munk Knudsen is targeting 800 million obese people globally.